JNJ-39220675

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525326

CAS#: 959740-39-7

Description: JNJ-39220675 is a novel selective histamine H3 receptor antagonist. JNJ-39220675 reduces the abuse-related effects of alcohol in rats.

Chemical Structure

img
JNJ-39220675
CAS# 959740-39-7
Instruction

Theoretical Analysis

MedKoo Cat#: 525326
Name: JNJ-39220675
CAS#: 959740-39-7
Chemical Formula: C21H24FN3O2
Exact Mass: 369.19
Molecular Weight: 369.430
Elemental Analysis: C, 68.27; H, 6.55; F, 5.14; N, 11.37; O, 8.66

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: JNJ-39220675; JNJ 39220675; JNJ39220675.

IUPAC/Chemical Name: (4-cyclobutyl-1,4-diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-3-yl)methanone

InChi Key: IQOWHZHNGJXGHG-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2

SMILES Code: O=C(N1CCCN(C2CCC2)CC1)c3cnc(Oc4ccc(F)cc4)cc3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 369.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nuutinen S, Panula P, Salminen O. Different Hypothalamic Nicotinic α7 Receptor Expression and Response to Low Nicotine Dose in Alcohol-Preferring and Alcohol-Avoiding Rats. Alcohol Clin Exp Res. 2016 Feb;40(2):329-34. doi: 10.1111/acer.12960. PubMed PMID: 26842251.

2: Vanhanen J, Kinnunen M, Nuutinen S, Panula P. Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs. Psychopharmacology (Berl). 2015 Mar;232(6):1143-53. doi: 10.1007/s00213-014-3751-7. Epub 2014 Oct 12. PubMed PMID: 25308376.

3: Barchuk WT, Salapatek AM, Ge T, D'Angelo P, Liu X. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol. 2013 Oct;132(4):838-46.e1-6. doi: 10.1016/j.jaci.2013.05.001. Epub 2013 Jun 20. PubMed PMID: 23791513.

4: Vanhanen J, Nuutinen S, Lintunen M, Mäki T, Rämö J, Karlstedt K, Panula P. Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation. Br J Pharmacol. 2013 Sep;170(1):177-87. doi: 10.1111/bph.12170. PubMed PMID: 23489295; PubMed Central PMCID: PMC3764859.

5: Logan J, Carruthers NI, Letavic MA, Sands S, Jiang X, Shea C, Muench L, Xu Y, Carter P, King P, Fowler JS. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon. Psychopharmacology (Berl). 2012 Oct;223(4):447-55. Epub 2012 May 22. PubMed PMID: 22614669; PubMed Central PMCID: PMC3456925.

6: Rezvani AH, Lawrence AJ, Arolfo MP, Levin ED, Overstreet DH. Novel medication targets for the treatment of alcoholism: preclinical studies. Recent Pat CNS Drug Discov. 2012 Aug;7(2):151-62. Review. PubMed PMID: 22574676.

7: Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. doi: 10.1007/s00213-010-2092-4. Epub 2010 Nov 18. PubMed PMID: 21086115.

8: Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, Everson A, Feinstein MA, Fraser IC, Hoey K, Jiang X, Keith JM, Koudriakova T, Leung P, Lord B, Lovenberg TW, Ly KS, Morton KL, Motley ST, Nepomuceno D, Rizzolio M, Rynberg R, Sepassi K, Shelton J. Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical development. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4210-4. doi: 10.1016/j.bmcl.2010.05.041. Epub 2010 May 16. PubMed PMID: 20561786.